GRAIL, Inc. (NASDAQ:GRAL – Get Free Report) CFO Aaron Freidin sold 3,000 shares of the stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $107.62, for a total transaction of $322,860.00. Following the sale, the chief financial officer owned 222,364 shares in the company, valued at approximately $23,930,813.68. This trade represents a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aaron Freidin also recently made the following trade(s):
- On Monday, October 5th, Aaron Freidin sold 23,619 shares of GRAIL stock. The shares were sold at an average price of $146.39, for a total transaction of $3,457,585.41.
- On Monday, September 21st, Aaron Freidin sold 4,100 shares of GRAIL stock. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00.
- On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The stock was sold at an average price of $85.01, for a total transaction of $671,579.00.
GRAIL Stock Performance
NASDAQ:GRAL opened at $105.88 on Wednesday. GRAIL, Inc. has a 52 week low of $41.50 and a 52 week high of $166.48. The company has a fifty day simple moving average of $122.50 and a two-hundred day simple moving average of $79.77.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on GRAL shares. Wall Street Zen upgraded GRAIL from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Canaccord Genuity Group lifted their price objective on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Robert W. Baird lifted their price objective on GRAIL from $96.00 to $118.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Morgan Stanley boosted their price objective on GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a research report on Monday, October 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $128.80.
View Our Latest Research Report on GRAL
Institutional Investors Weigh In On GRAIL
Hedge funds and other institutional investors have recently modified their holdings of the company. Primecap Management Co. CA purchased a new stake in shares of GRAIL during the 2nd quarter worth approximately $148,836,000. Bank of America Corp DE acquired a new position in shares of GRAIL in the 2nd quarter valued at $49,389,000. BlackRock Inc. boosted its holdings in shares of GRAIL by 20.5% in the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after buying an additional 608,539 shares in the last quarter. State Street Corp boosted its holdings in shares of GRAIL by 26.1% in the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after buying an additional 493,621 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of GRAIL by 88.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 408,650 shares of the company’s stock valued at $21,104,000 after buying an additional 191,857 shares during the last quarter.
GRAIL Company Profile
GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.
Recommended Stories
- Five stocks we like better than GRAIL
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
